IP Library Granted Patent US 8,993,760
Granted Patent B2
US 8,993,760 · App. 12/488,826 · Granted Mar 31, 2015

Rock inhibitors and uses thereof

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 8,993,760
App. No.
12/488,826
Granted
Mar 31, 2015
Kind
B2
Abstract

The subject invention concerns compositions and methods for blocking cancer cell growth or proliferation and/or inducing cancer cell death. Compositions of the present invention are compounds that inhibit Rho-protein associated kinase function. Compounds of the invention include piperazinyl pyridines, piperazinylmethyl pyridines, piperazinyl ureas and carbamates, piperazinyl pyridines and quinoilines (including isoquinliones) as well as piperazinyl (including piperazinylmethyl) pyridines and quinolines (including isoquinolines). Compounds of the invention disrupt Rho-kinase activation and function and significantly inhibit tumor cell growth and induce tumor cell death.

Claims (17)

1. A compound having the structure shown in formula I:

wherein R 1 is pyridyl;

wherein R 2 is selected from the group consisting of Bn, CH 2 OBn, i-propane, butane, OBn, Ph, H, CH 2 CH 2 SMe, CH(CH 3 )OH, and a salt thereof;

wherein R 3 is selected from the group consisting of CH 3 , butoxycarbonyl, H,

COCH 2 NH-y, H, and a salt thereof,

where y is a protecting group; and

where R 2 and R 3 are not concurrently H.

2. The compound of claim 1 wherein R 2 is selected from the group consisting of Bn, CH 2 OBn, Me, i-Pr, -Bu, OBn and Ph, and a salt thereof.

3. The compound of claim 1 wherein R 3 is selected from the group consisting of CH 3 , butoxycarbonyl, H, and COCH 2 NHBoc, and a salt thereof.

4. A compound having the structure shown in formula II;

wherein R 1 is selected from the group consisting of pyridyl and methylpyridyl;

wherein R 2 is selected from the group consisting of CH(CH 3 )OH, CH 2 Ph, CH 2 CH 2 SMe, CH 2 OH, butyl, i-butyl, propyl, i-propyl, and a salt thereof; and

R 3 is selected from the group consisting of C═O, CH 2 , CH-halo, and C(CH 3 ) 2 .

5. The compound of claim 4 wherein R 1 is methylpyridyl.

6. The Compound of claim 4 wherein R 2 is selected from the group consisting of CH(CH 3 )OH, butyl, i-butyl, propyl, i-propyl and (CH 2 ) 2 SCH 3 ; and

wherein R 3 is selected from the group consisting of C═O, CH 2 , CH-halo, and C(CH 3 ) 2 .

7. The compound of claim 4 selected from the group consisting of:

Assignments (3)
CONFIRMATORY LICENSE Recorded Apr 30, 2010
From: H. LEE MOFFITT CANCER CTR & RESEARCH INS
To: NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT
Reel/Frame 024316/0868 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Oct 26, 2009
From: HAMILTON, ANDREW D.
To: YALE UNIVERSITY
Reel/Frame 023423/0173 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Sep 4, 2009
From: SEBTI, SAID
To: UNIVERSITY OF SOUTH FLORIDA
Reel/Frame 023365/0077 →